Arvinas Holding Company (ARVN) has issued an announcement.
Arvinas, Inc. and Pfizer have revealed promising results from their Phase 1b trial of vepdegestrant combined with palbociclib (IBRANCE®) in treating ER+/HER2- breast cancer in patients with multiple prior lines of therapy. The latest follow-up data, consistent with earlier findings, showed a high clinical benefit rate and an overall response rate, with a median progression-free survival of over 11 months, which extended to nearly 14 months at the recommended Phase 3 dose. These outcomes, presented at the 2024 ESMO Breast Cancer Annual Congress, coupled with a manageable safety profile, indicate the potential of this treatment regimen in heavily pre-treated breast cancer patients.
See more insights into ARVN stock on TipRanks’ Stock Analysis page.
